3.5 Integrated Case Study: Diagnosing & Remedying Prescription Drug Cost Increases
Key Takeaways
- Pharmacy trend decomposes into utilization change, unit-cost change, and mix shift; the remedy depends entirely on which component is driving the increase, so decomposition must precede any plan-design change.
- A double-digit pharmacy increase with flat scripts per member per year and rising cost per script points to specialty mix shift, not overutilization, and cost-sharing changes will not fix it.
- Specialty drugs typically represent a low single-digit percentage of prescriptions but roughly half or more of total pharmacy spend, which is why per-script averages conceal the real driver.
- Effective specialty remedies are channel and site-of-care management, prior authorization with clinical criteria, biosimilar preference, and outcomes-based contracting — not blunt copay increases, which shift cost to the sickest members and can trigger nonadherence.
- Any PBM remedy must be tested against the contract: definitions of generic, brand, and specialty, rebate pass-through, spread pricing, and audit rights determine whether a negotiated 'discount improvement' produces real savings.
Integrated Case Study: Diagnosing & Remedying Prescription Drug Cost Increases
Quick Answer: Pharmacy cost increases are diagnosed by decomposing trend into utilization, unit cost, and mix. Flat utilization with a rising average cost per script signals a specialty mix shift, which cost-sharing changes cannot cure. The remedy set is channel and site-of-care management, prior authorization, biosimilar preference, and contract remediation with the PBM — evaluated against the plan's fiduciary duty and the members' adherence risk.
1. The Scenario
Cascadia Instruments is a 2,400-employee self-funded manufacturer, roughly 5,100 covered lives, with an integrated PBM arrangement bundled with its medical TPA. The CFO has flagged a pharmacy line that rose 18.4% year over year while medical trend held at 6.1%. The benefits committee's first instinct is to add a fourth copay tier and raise the specialty copay from $100 to $250.
The CEBS-trained analyst's first move is not to redesign anything. It is to decompose the trend.
2. Decomposing Pharmacy Trend
Pharmacy trend is the product of three factors, not a single number:
- Utilization — scripts per member per year (PMPY). Answers: are members filling more prescriptions?
- Unit cost — net cost per script within a constant drug mix. Answers: did prices rise on the same drugs?
- Mix — the distribution of scripts across generic, brand, and specialty. Answers: did the population shift toward more expensive therapies?
Cascadia's Data
| Metric | Prior Year | Current Year | Change |
|---|---|---|---|
| Scripts per member per year | 11.8 | 11.9 | +0.8% |
| Generic dispensing rate (GDR) | 88.1% | 89.4% | +1.3 pts |
| Average net cost per script | $71.40 | $83.90 | +17.5% |
| Specialty scripts as % of total | 1.4% | 2.1% | +0.7 pts |
| Specialty spend as % of total | 48% | 57% | +9 pts |
| Net plan pharmacy cost PMPM | $70.20 | $83.11 | +18.4% |
Read the evidence. Utilization is essentially flat. The generic dispensing rate improved, which normally suppresses cost. Yet cost per script rose 17.5% and specialty went from 48% to 57% of spend on 2.1% of scripts. This is a textbook mix shift, concentrated in specialty. The proposed fourth copay tier addresses none of it.
Why the Copay Increase Fails
Raising the specialty copay from $100 to $250 across roughly 107 specialty utilizers recovers on the order of $190,000 annually — under 5% of the increase — while imposing the entire burden on the sickest members. Specialty cost-sharing increases are also strongly associated with primary nonadherence (prescriptions never picked up), which for conditions such as rheumatoid arthritis or multiple sclerosis reliably converts pharmacy savings into larger medical claims. It is a cost shift, not a cost control.
3. Building the Remedy Set
| Lever | Mechanism | Where It Bites | Typical Constraint |
|---|---|---|---|
| Prior authorization & step therapy | Clinical criteria before high-cost agents; require preferred agent first | New specialty starts | Must not violate MHPAEA NQTL parity for behavioral-health drugs; needs an expedited appeals path |
| Biosimilar preference | Formulary places biosimilars at a preferred tier or requires them first | Biologics with approved biosimilars | Interchangeability and provider resistance; requires member communication |
| Site-of-care management | Redirect infused drugs from hospital outpatient to home infusion or physician office | Medical-benefit specialty drugs | Requires medical-plus-pharmacy data; hospital contract terms may lock in outpatient administration |
| Specialty pharmacy channel | Exclusive specialty network with clinical support and split-fill programs | Dispensing margin and waste | Narrows member choice; disruption analysis required |
| Outcomes-based contracts | Manufacturer rebate contingent on clinical response | High-cost, measurable-outcome therapies | Needs data infrastructure and sufficient volume |
| Copay assistance coordination | Structured handling of manufacturer coupons and patient assistance | Member out-of-pocket | Accumulator and maximizer designs raise fiduciary, ACA out-of-pocket, and state-law questions |
Do not forget the medical benefit. At Cascadia, roughly 40% of specialty spend is billed under the medical benefit as physician-administered infusions and never appears in a pharmacy report at all. Any analysis built solely on PBM data will understate specialty exposure and miss the largest site-of-care opportunity.
4. Testing the PBM Contract
A negotiated "better discount" is meaningless until the contract definitions are examined. Four provisions decide whether savings are real:
- Definitions of generic, brand, and specialty. If the PBM can reclassify a drug between buckets, guaranteed discount percentages can be met while total spend rises. Insist on a fixed, contractually attached specialty drug list with a change-control process.
- Rebate pass-through. Distinguish "rebates" from "manufacturer administrative fees," "data fees," and "purchase discounts." A 100% rebate pass-through that excludes three other revenue categories is not transparent pricing.
- Spread pricing. Under a traditional spread model the PBM bills the plan more than it reimburses the pharmacy and keeps the difference. A pass-through or transparent model eliminates spread but usually carries a higher explicit administrative fee — the comparison must be on net cost, not on the admin line.
- Audit rights. The right to audit claims and rebates, using an auditor of the plan's choosing, with a workable look-back period and no unreasonable sampling limits.
5. The Recommendation
The committee's decision memo should reject the fourth copay tier as the primary remedy and instead: (1) implement prior authorization and step therapy on new specialty starts with an expedited clinical appeal; (2) adopt biosimilar-preferred placement; (3) launch site-of-care redirection for medical-benefit infusions after a combined medical-and-pharmacy data build; (4) renegotiate PBM definitions, rebate pass-through, and audit rights at the next contract window; and (5) hold member cost-sharing on specialty flat, on the documented grounds that nonadherence risk outweighs the modest recovery. Each step is recorded in committee minutes — the procedural-prudence record that a benefits fiduciary will need if the decision is later challenged.
A self-funded plan's pharmacy spend rose 18% year over year. Scripts per member per year were flat, the generic dispensing rate improved by 1.3 points, average net cost per script rose 17.5%, and specialty grew from 48% to 57% of total pharmacy spend on 2.1% of prescriptions. What is the driver, and what does that rule out?
Why does raising a specialty copay from $100 to $250 typically fail as the primary response to specialty-driven pharmacy trend?
A benefits committee reviews a PBM proposal guaranteeing a deeper average discount off AWP on specialty drugs. Which contract provision most directly determines whether that guarantee produces real savings?